# Rapid Micro Biosystems, Inc.: financial statements, quarterly

RPID · Nasdaq · CIK 1380106 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rpid.md) · [Financials](/companies/rpid/financials.md) · [Filings](/companies/rpid/filings.md) · [Insiders](/companies/rpid/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rpid/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.1](/filings/0001380106-24-000197.md) | [6.3 d](/filings/0001380106-25-000058.md) | [5.6](/filings/0001380106-25-000102.md) | [6.6](/filings/0001380106-25-000174.md) | [7.6](/filings/0001380106-25-000200.md) | [8.2 d](/filings/0001380106-26-000034.md) | [7.2](/filings/0001380106-26-000075.md) | [7.3](/filings/0001380106-26-000101.md) | [7.8](/filings/0001380106-25-000200.md) | [11.3 d](/filings/0001380106-26-000034.md) | [8.0](/filings/0001380106-26-000075.md) | [8.1](/filings/0001380106-26-000101.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [6.8](/filings/0001380106-26-000075.md) | [7.0](/filings/0001380106-26-000101.md) | not reported | not reported | [7.6](/filings/0001380106-26-000075.md) | [6.8](/filings/0001380106-26-000101.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.4](/filings/0001380106-26-000075.md) | [0.3](/filings/0001380106-26-000101.md) | not reported | not reported | [0.4](/filings/0001380106-26-000075.md) | [1.2](/filings/0001380106-26-000101.md) |
| Research and development | $m | [3.1](/filings/0001380106-24-000197.md) | [3.3 d](/filings/0001380106-25-000058.md) | [3.8](/filings/0001380106-25-000102.md) | [3.7](/filings/0001380106-25-000174.md) | [3.6](/filings/0001380106-25-000200.md) | [3.4 d](/filings/0001380106-26-000034.md) | [3.6](/filings/0001380106-26-000075.md) | [3.2](/filings/0001380106-26-000101.md) | [3.5](/filings/0001380106-25-000200.md) | [3.2 d](/filings/0001380106-26-000034.md) | [3.4](/filings/0001380106-26-000075.md) | [3.3](/filings/0001380106-26-000101.md) |
| Operating income | $m | [(14.4)](/filings/0001380106-24-000197.md) | [(12.2) d](/filings/0001380106-25-000058.md) | [(14.3)](/filings/0001380106-25-000102.md) | [(13.4)](/filings/0001380106-25-000174.md) | [(12.0)](/filings/0001380106-25-000200.md) | [(10.2) d](/filings/0001380106-26-000034.md) | [(11.7)](/filings/0001380106-26-000075.md) | [(12.1)](/filings/0001380106-26-000101.md) | [(11.4)](/filings/0001380106-25-000200.md) | [(12.2) d](/filings/0001380106-26-000034.md) | [(13.9)](/filings/0001380106-26-000075.md) | [(12.3)](/filings/0001380106-26-000101.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001380106-25-000200.md) | [0.0 d](/filings/0001380106-26-000034.md) | [0.0](/filings/0001380106-26-000075.md) | [0.0](/filings/0001380106-26-000101.md) | [0.4](/filings/0001380106-25-000200.md) | [0.7 d](/filings/0001380106-26-000034.md) | [0.6](/filings/0001380106-26-000075.md) | [0.6](/filings/0001380106-26-000101.md) |
| Income tax | $m | [0.0](/filings/0001380106-24-000197.md) | [0.0 d](/filings/0001380106-25-000058.md) | [0.0](/filings/0001380106-25-000102.md) | [0.0](/filings/0001380106-25-000174.md) | [0.0](/filings/0001380106-25-000200.md) | [(0.0) d](/filings/0001380106-26-000034.md) | [0.0](/filings/0001380106-26-000075.md) | [0.0](/filings/0001380106-26-000101.md) | [0.0](/filings/0001380106-25-000200.md) | [0.0 d](/filings/0001380106-26-000034.md) | [0.0](/filings/0001380106-26-000075.md) | [0.0](/filings/0001380106-26-000101.md) |
| Net income | $m | [(13.4)](/filings/0001380106-24-000197.md) | [(11.2) d](/filings/0001380106-25-000058.md) | [(13.3)](/filings/0001380106-25-000200.md) | [(12.6)](/filings/0001380106-25-000200.md) | [(11.3)](/filings/0001380106-25-000200.md) | [(9.7) d](/filings/0001380106-26-000034.md) | [(11.3)](/filings/0001380106-26-000101.md) | [(11.9)](/filings/0001380106-26-000101.md) | [(11.5)](/filings/0001380106-25-000200.md) | [(12.5) d](/filings/0001380106-26-000034.md) | [(14.3)](/filings/0001380106-26-000101.md) | [(12.9)](/filings/0001380106-26-000101.md) |
| Diluted EPS | $ per share | [(0.31)](/filings/0001380106-24-000197.md) | not reported | [(0.31)](/filings/0001380106-25-000102.md) | [(0.29)](/filings/0001380106-25-000174.md) | [(0.26)](/filings/0001380106-25-000200.md) | not reported | [(0.26)](/filings/0001380106-26-000075.md) | [(0.27)](/filings/0001380106-26-000101.md) | [(0.26)](/filings/0001380106-25-000200.md) | not reported | [(0.31)](/filings/0001380106-26-000075.md) | [(0.27)](/filings/0001380106-26-000101.md) |
| Basic EPS | $ per share | [(0.31)](/filings/0001380106-24-000197.md) | not reported | [(0.31)](/filings/0001380106-25-000102.md) | [(0.29)](/filings/0001380106-25-000174.md) | [(0.26)](/filings/0001380106-25-000200.md) | not reported | [(0.26)](/filings/0001380106-26-000075.md) | [(0.27)](/filings/0001380106-26-000101.md) | [(0.26)](/filings/0001380106-25-000200.md) | not reported | [(0.31)](/filings/0001380106-26-000075.md) | [(0.27)](/filings/0001380106-26-000101.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [23.8](/filings/0001380106-23-000177.md) | [24.3](/filings/0001380106-25-000058.md) | [22.4](/filings/0001380106-24-000127.md) | [37.1](/filings/0001380106-24-000166.md) | [22.0](/filings/0001380106-24-000197.md) | [16.9](/filings/0001380106-26-000034.md) | [18.9](/filings/0001380106-25-000102.md) | [18.3](/filings/0001380106-25-000174.md) | [18.9](/filings/0001380106-25-000200.md) | [20.0](/filings/0001380106-26-000101.md) | [13.8](/filings/0001380106-26-000075.md) | [14.7](/filings/0001380106-26-000101.md) |
| Current assets | $m | [115](/filings/0001380106-23-000177.md) | [120](/filings/0001380106-25-000058.md) | [108](/filings/0001380106-24-000127.md) | [98.2](/filings/0001380106-24-000166.md) | [87.9](/filings/0001380106-24-000197.md) | [80.9](/filings/0001380106-26-000034.md) | [69.2](/filings/0001380106-25-000102.md) | [60.1](/filings/0001380106-25-000174.md) | [70.0](/filings/0001380106-25-000200.md) | [61.2](/filings/0001380106-26-000101.md) | [49.2](/filings/0001380106-26-000075.md) | [46.3](/filings/0001380106-26-000101.md) |
| Total assets | $m | [150](/filings/0001380106-23-000177.md) | [143](/filings/0001380106-25-000058.md) | [128](/filings/0001380106-24-000127.md) | [117](/filings/0001380106-24-000166.md) | [106](/filings/0001380106-24-000197.md) | [98.2](/filings/0001380106-26-000034.md) | [85.4](/filings/0001380106-25-000102.md) | [75.6](/filings/0001380106-25-000174.md) | [84.4](/filings/0001380106-25-000200.md) | [74.9](/filings/0001380106-26-000101.md) | [62.4](/filings/0001380106-26-000075.md) | [58.5](/filings/0001380106-26-000101.md) |
| Current liabilities | $m | [15.6](/filings/0001380106-23-000177.md) | [19.0](/filings/0001380106-25-000058.md) | [15.6](/filings/0001380106-24-000127.md) | [16.6](/filings/0001380106-24-000166.md) | [15.9](/filings/0001380106-24-000197.md) | [17.6](/filings/0001380106-26-000034.md) | [15.0](/filings/0001380106-25-000102.md) | [16.4](/filings/0001380106-25-000174.md) | [16.5](/filings/0001380106-25-000200.md) | [18.5](/filings/0001380106-26-000101.md) | [19.1](/filings/0001380106-26-000075.md) | [18.2](/filings/0001380106-26-000101.md) |
| Total liabilities | $m | [22.4](/filings/0001380106-23-000177.md) | [25.5](/filings/0001380106-25-000058.md) | [21.8](/filings/0001380106-24-000127.md) | [22.5](/filings/0001380106-24-000166.md) | [21.5](/filings/0001380106-24-000197.md) | [22.8](/filings/0001380106-26-000034.md) | [19.9](/filings/0001380106-25-000102.md) | [21.0](/filings/0001380106-25-000174.md) | [40.1](/filings/0001380106-25-000200.md) | [41.6](/filings/0001380106-26-000101.md) | [42.0](/filings/0001380106-26-000075.md) | [40.7](/filings/0001380106-26-000101.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001380106-26-000034.md) | not reported | not reported | [18.8](/filings/0001380106-25-000200.md) | [18.9](/filings/0001380106-26-000101.md) | [19.1](/filings/0001380106-26-000075.md) | [19.1](/filings/0001380106-26-000101.md) |
| Shareholders' equity | $m | [128](/filings/0001380106-24-000197.md) | [118](/filings/0001380106-26-000034.md) | [106](/filings/0001380106-25-000200.md) | [94.6](/filings/0001380106-25-000200.md) | [84.4](/filings/0001380106-25-000200.md) | [75.4](/filings/0001380106-26-000101.md) | [65.5](/filings/0001380106-26-000101.md) | [54.5](/filings/0001380106-26-000101.md) | [44.3](/filings/0001380106-25-000200.md) | [33.2](/filings/0001380106-26-000101.md) | [20.4](/filings/0001380106-26-000101.md) | [17.7](/filings/0001380106-26-000101.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.7) d](/filings/0001380106-24-000197.md) | [(9.5) d](/filings/0001380106-25-000058.md) | [(15.5)](/filings/0001380106-25-000102.md) | [(10.1) d](/filings/0001380106-25-000174.md) | [(8.6) d](/filings/0001380106-25-000200.md) | [(9.9) d](/filings/0001380106-26-000034.md) | [(9.1)](/filings/0001380106-26-000075.md) | [(9.7) d](/filings/0001380106-26-000101.md) | [(9.1) d](/filings/0001380106-25-000200.md) | [(3.2) d](/filings/0001380106-26-000034.md) | [(15.1)](/filings/0001380106-26-000075.md) | [(12.7) d](/filings/0001380106-26-000101.md) |
| Capital expenditure | $m | [0.5 d](/filings/0001380106-24-000197.md) | [0.4 d](/filings/0001380106-25-000058.md) | [0.6](/filings/0001380106-25-000102.md) | [0.5 d](/filings/0001380106-25-000174.md) | [0.2 d](/filings/0001380106-25-000200.md) | [0.1 d](/filings/0001380106-26-000034.md) | [0.3](/filings/0001380106-26-000075.md) | [0.4 d](/filings/0001380106-26-000101.md) | [0.1 d](/filings/0001380106-25-000200.md) | [0.1 d](/filings/0001380106-26-000034.md) | [0.4](/filings/0001380106-26-000075.md) | [(0.2) d](/filings/0001380106-26-000101.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [42.5](/filings/0001380106-23-000177.md) | [42.8](/filings/0001380106-24-000127.md) | [43.1](/filings/0001380106-24-000166.md) | [43.1](/filings/0001380106-24-000197.md) | [43.2](/filings/0001380106-25-000102.md) | [43.6](/filings/0001380106-25-000174.md) | [43.7](/filings/0001380106-25-000200.md) | [44.0](/filings/0001380106-26-000075.md) | [44.6](/filings/0001380106-26-000101.md) | [45.0](/filings/0001380106-25-000200.md) | [45.4](/filings/0001380106-26-000075.md) | [48.3](/filings/0001380106-26-000101.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.